Yuanita Emmy, Dharmayani Ni Komang Tri, Ulfa Maria, Syahri Jufrizal
Department of Chemistry, Universitas Mataram, Majapahit Street 62, Mataram 83236, Indonesia.
Department of Chemistry, Universitas Muhammadiyah Riau, Tuanku Tambusai Street, Pekanbaru, Indonesia.
J Clin Tuberc Other Mycobact Dis. 2020 Nov 16;21:100203. doi: 10.1016/j.jctube.2020.100203. eCollection 2020 Dec.
Quantitative structure-activity relationship (QSAR) and molecular docking approach were carried out to design novel anti-tuberculosis agents based on xanthone derivatives. QSAR designed new compounds were calculated by Austin Model 1 (AM1) methods and analysis of multi-linear regression (MLR). The result showed that the best model as follows: Log IC50 = 3.113 + 11.627 qC1 + 15.955 qC4 + 11.702 qC9, this result has appropriate some statistical parameters (PRESS = 2.11, r2 = 0.730, SEE = 0. 3545, R = 0.6827, FCal/FTab = 4.68), and being used to design a potential anti-tuberculosis drugs with substituted amide, sulfoxide, and carboxylate group xanthone scaffold by a number of their inhibitory concentration (IC50). The mechanism action of sulfonamide substituted on the xanthone scaffold as anti-tuberculosis was carried out using molecular docking. Docking inhibition studies were carried out on MTB C171Q receptor (4C6X.pdb) as KasA inhibitors using by the discovery studio. Based on the binding interaction showed, the sulfonamide substituted xanthone has potential being the anti-tuberculosis drugs by KasA inhibitor for target drug activity.
采用定量构效关系(QSAR)和分子对接方法,基于氧杂蒽衍生物设计新型抗结核药物。通过奥斯汀模型1(AM1)方法和多元线性回归(MLR)分析对QSAR设计的新化合物进行计算。结果表明最佳模型如下:Log IC50 = 3.113 + 11.627 qC1 + 15.955 qC4 + 11.702 qC9,该结果具有合适的一些统计参数(PRESS = 2.11,r2 = 0.730,SEE = 0.3545,R = 0.6827,FCal/FTab = 4.68),并用于通过多种抑制浓度(IC50)设计具有取代酰胺、亚砜和羧基氧杂蒽支架的潜在抗结核药物。利用分子对接研究了氧杂蒽支架上取代的磺酰胺作为抗结核药物的作用机制。使用发现工作室对作为KasA抑制剂的MTB C171Q受体(4C6X.pdb)进行对接抑制研究。基于所显示的结合相互作用,取代磺酰胺的氧杂蒽有潜力作为针对目标药物活性的KasA抑制剂成为抗结核药物。